The themes Johnson & Johnson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
InspectStocks tarafından · 20 companies
Surgical robots, implants, heart devices, glucose monitors and other medical equipment.
A 8B 7C 3D 2
InspectStocks tarafından · 13 companies
The largest drugmakers, selling prescription medicines worldwide.
A 7B 3C 3
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Gelir payları six months ended June 28, 2026, high confidence dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.
VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.
Johnson & Johnson develops, makes and sells prescription medicines and medical devices around the world. Its two businesses are Innovative Medicine, which sells medicines for conditions including cancer and immune disorders, and MedTech, which sells products used in heart procedures, surgery, orthopaedics and vision care.
Johnson & Johnson şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
$286,06+%0,913 Kas kapanış
27 Eylül 2026 tarihine kadarki rakamlar, 21 Ekim 2026 tarihinde sunulan 10-Q raporundan
Makes prescription medicines and medical devices for cancer, immune disorders, surgery, heart care, joint replacement and vision.
Grade A+
Fiyatın altındaki şerit, her tarihteki notu gösterir; yalnızca o tarihe kadar yayımlanmış belgelerden hesaplanır.
Johnson & Johnson şirketinin not geçmişinin 41 çeyreğinden 2 tanesi gösteriliyor. Diğer 39 çeyrek Kasım 2016 tarihine kadar uzanıyor.